Monday April 1, 2019 0 comments
WESTMINSTER -- Flagship Biosciences and Germany-based Indivumed announced a partnership to expand their broad tissue-based biomarker development capabilities, as well as their clinical services to support advanced oncology diagnostics.
Under the terms of the agreement, the companies will offer a comprehensive set of services combining Flagship’s extensive experience in biomarker development and Indivumed’s multiplex immunohistochemistry (IHC) assay development capabilities.
In addition, Indivumed’s client base will benefit from Flagship’s artificial intelligence-enabled computational tissue analysis (cTA®) digital pathology platform, which provides complimentary and comprehensive tissue profiling.
The complexity of tumor/immune interactions is creating a growing need to leverage advanced IHC services. Flagship said its platform will allow Indivumed’s clients to derive more accurate and informative data from their tissue samples.
This joint effort will also expand Indivumed’s portfolio of services by providing full College of American Pathologists (CAP) accredited and Clinical Laboratory Improvement Amendments (CLIA) certified testing capabilities.
Both Indivumed and Flagship share a goal to help accelerate the development and deployment of new treatment and diagnostic tools and will keep exploring options to expand cooperation toward this goal.
“This is an exciting development for us,” said Dr. Hartmut Juhl, CEO of Indivumed. “Flagship has a high reputation as a supplier of advanced IHC services and their CAP-CLIA environment is a perfect complement to our own testing facilities in Hamburg.
“Furthermore, both companies are engaged in Artificial Intelligence and Machine Learning projects opening multiple opportunities for future collaboration.”
“We are honored to be teaming with Indivumed to expand services in the clinical space,” said Trevor Johnson, Flagship CEO.
“Indivumed is an ideal partner given their deep experience and leadership in the global oncology field. We are committed to advancing development in immune-oncology with the combined set of capabilities represented by this partnership.”